Psoriatic arthritis&nbsp;&nbsp;&nbsp;

Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?

How do you view it relative to existing options like TNFi, IL-23, or IL-17s like ixekizumab?

Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?

For example, in patients with many swollen/tender joints, enthesitis, nail involvement do you expect particularly good response? Are there patients in...

How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?

Would you use an anti-IL 17 over an anti-TNFa as your first line biologic in psoriatic arthritis?

Would you recommend avoiding use of bimekizumab in patients at higher risk of fungal infections such as patients with diabetes who are on SGLT-2 inhibitors which also increase the risk of fungal infections?

How will you counsel patients about the risk and what strategies will you use to mitigate the increased risk of fungal infections seen in the BE COMPL...

Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?

How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?

The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.

How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?

Is there any concern for drug interactions of DMARDs and/or biologics with anti seizure medications?

How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?

What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?

What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?

How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

4 Answers available

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

In clinical practice continued steroid dependence is often seen as a reason to switch therapy and providers can be especially hesitant to use systemic...

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

Based on the results of the DISCOVER-2 Trial (McInnes et al., PMID 34719872), should guselkumab be used prior to anti-TNF therapy in these patients?

What has been your experience using apremilast to treat mild to moderate psoriatic arthritis not controlled with NSAIDs?

What disease activity measures do you find helpful in clinical practice for psoriatic arthritis/peripheral spondyloarthritis?

Would you use an IL-17 inhibitor for a psoriatic arthritis patient with inactive inflammatory bowel disease?